- Report
- October 2023
- 145 Pages
Global
From €2867EUR$3,150USD£2,435GBP
- Report
- August 2023
- 145 Pages
Global
From €2867EUR$3,150USD£2,435GBP
- Report
- November 2023
- 337 Pages
Global
From €3277EUR$3,600USD£2,783GBP
- Report
- June 2023
- 224 Pages
Global
From €3277EUR$3,600USD£2,783GBP
- Report
- May 2022
- 332 Pages
Global
From €3277EUR$3,600USD£2,783GBP
- Report
- May 2022
- 127 Pages
Global
From €3277EUR$3,600USD£2,783GBP
- Report
- April 2020
- 166 Pages
Global
From €3277EUR$3,600USD£2,783GBP
- Report
- June 2021
Global
From €3641EUR$4,000USD£3,092GBP
- Report
- June 2021
Global
From €3641EUR$4,000USD£3,092GBP
- Report
- November 2023
- 190 Pages
Global
From €4505EUR$4,950USD£3,827GBP
- Report
- November 2023
- 109 Pages
Middle East, Africa
From €2685EUR$2,950USD£2,281GBP
- Book
- January 2020
North America
The Automated Insulin Delivery (AID) market is a subset of the larger diabetes devices market. AID systems are designed to help people with diabetes manage their condition by automatically delivering insulin to the body. These systems are typically composed of an insulin pump, a continuous glucose monitor (CGM), and a control algorithm. The CGM measures glucose levels in the body and sends the data to the control algorithm, which then calculates the amount of insulin needed and sends a signal to the insulin pump to deliver the appropriate dose.
AID systems are designed to provide more accurate and consistent insulin delivery than traditional methods, and can help reduce the risk of hypoglycemia and other diabetes-related complications. They are also designed to be user-friendly and provide users with more control over their diabetes management.
Some companies in the AID market include Medtronic, Insulet, Tandem Diabetes Care, Bigfoot Biomedical, and Senseonics. Show Less Read more